AU Patent

AU2024250257A1 — Methods and compositions for reducing symptoms of parkinson's disease

Assigned to Neuroderm Ltd · Expires 2025-11-27 · 0y expired

What this patent protects

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.

USPTO Abstract

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024250257A1
Jurisdiction
AU
Classification
—
Expires
2025-11-27
Drug substance claim
No
Drug product claim
No
Assignee
Neuroderm Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.